GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

Mon, 18 May 2026 09:15:00 -0400

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026

Register for the event here

LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

Mon, 18 May 2026 09:15:00 -0400

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026

Register for the event here

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

Mon, 18 May 2026 09:15:00 -0400

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026

Register for the event here

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

Mon, 18 May 2026 09:15:00 -0400

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026

Register for the event here

Form 8-K GRI Bio, Inc. For: May 14

Thu, 14 May 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260514/26490730.html

Form 8-K GRI Bio, Inc. For: May 14

Thu, 14 May 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260514/26490730.html

GRI Bio reports Q1 2026 results, advances drug pipeline

Thu, 14 May 2026 08:35:34 -0400

GRI Bio Inc. (NASDAQ: GRI) reported first quarter 2026 financial results and provided updates on its drug development programs. The biotechnology company focuses on Natural Killer T cell modulators for inflammatory, fibrotic and autoimmune diseases.

The company reported cash and cash equivalents of approximately $11.0 million as of March 31, 2026, compared to $8.2 million at December 31, 2025. GRI Bio expects current cash resources will fund planned operations into the second quarter of 2027.

Net loss for the quarter was approximately $2.0 million, compared to $3.0 million in the same period of 2025. Research and development expenses decreased to $0.4 million

GRI Bio reports Q1 2026 results, advances drug pipeline

Thu, 14 May 2026 08:35:34 -0400

Net loss for the quarter was approximately $2.0 million, compared to $3.0 million in the same period of 2025. Research and development expenses decreased to $0.4 million

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Im

Thu, 14 May 2026 08:35:00 -0400

Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities when used in combination

Advancing GRI-0803 toward IND-enabling activities to expand the pipeline across autoimmune indications with high unmet need

LA JOLLA, CA, May 14, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Im

Thu, 14 May 2026 08:35:00 -0400

Advancing GRI-0803 toward IND-enabling activities to expand the pipeline across autoimmune indications with high unmet need

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Im

Thu, 14 May 2026 08:35:00 -0400

Advancing GRI-0803 toward IND-enabling activities to expand the pipeline across autoimmune indications with high unmet need

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Im

Thu, 14 May 2026 08:35:00 -0400

Advancing GRI-0803 toward IND-enabling activities to expand the pipeline across autoimmune indications with high unmet need

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Wed, 13 May 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260513/26487000.html

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Wed, 13 May 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260513/26487000.html

Form 10-Q GRI Bio, Inc. For: Mar 31

Wed, 13 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260513/26486311.html

Form 10-Q GRI Bio, Inc. For: Mar 31

Wed, 13 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260513/26486311.html

GRI Bio receives UAE patent allowance for NKT cell agonists

Wed, 08 Apr 2026 08:30:25 -0400

GRI Bio Inc. (NASDAQ: GRI) announced it received a Notice of Allowance from the United Arab Emirates Patent Office for UAE Patent No. P6000687/2017, titled "Prevention and Treatment of Inflammatory Conditions."

The allowed claims cover novel type 2 diverse NKT cell agonists and related methods and compositions for preventing and treating inflammatory conditions. The patent expands GRI Bio's intellectual property protection for its immunomodulatory platform targeting immune pathways in inflammatory, fibrotic and autoimmune diseases.

"This Notice of Allowance reflects the continued execution of our disciplined global IP strategy," said Marc Hertz, Chief Executive Officer of GRI Bio. "Securing protection in key international

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Wed, 08 Apr 2026 08:30:00 -0400

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market

LA JOLLA, CA, April 08, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it has received a Notice of Allowance from the United Arab Emirates Patent Office (UAE) for UAE Patent No. P6000687/2017, titled “Prevention and Treatment of

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Wed, 08 Apr 2026 08:30:00 -0400

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market

LA JOLLA, CA, April 08, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it has received a Notice of Allowance from the United Arab Emirates Patent Office (UAE) for UAE Patent No. P6000687/2017, titled “Prevention and Treatment of

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Tue, 17 Feb 2026 09:15:00 -0400

Access the “What This Means” segment here

LA JOLLA, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor “What This Means” segment.

As part of the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI Bio, discussed important

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Tue, 17 Feb 2026 09:15:00 -0400

Access the “What This Means” segment here

LA JOLLA, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor “What This Means” segment.

As part of the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI Bio, discussed important

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Fri, 13 Feb 2026 16:43:00 -0400
si-local-file:///var/storage/secattach/20260213/26001372.html

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Fri, 13 Feb 2026 16:43:00 -0400
si-local-file:///var/storage/secattach/20260213/26001372.html

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: Lincoln Alternative Strategies LLC

Tue, 10 Feb 2026 14:11:00 -0400
si-local-file:///var/storage/secattach/20260210/25974609.html

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: Lincoln Alternative Strategies LLC

Tue, 10 Feb 2026 14:11:00 -0400
si-local-file:///var/storage/secattach/20260210/25974609.html

StreetInsider.com News Articles

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

Form 8-K GRI Bio, Inc. For: May 14

Form 8-K GRI Bio, Inc. For: May 14

GRI Bio reports Q1 2026 results, advances drug pipeline

GRI Bio reports Q1 2026 results, advances drug pipeline

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Im

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Im

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Im

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Im

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Form 10-Q GRI Bio, Inc. For: Mar 31

Form 10-Q GRI Bio, Inc. For: Mar 31

GRI Bio receives UAE patent allowance for NKT cell agonists

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: Lincoln Alternative Strategies LLC

Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: Lincoln Alternative Strategies LLC